Affimed N.V. announced that two abstracts with its innate cell engager (ICE(R)) AFM24 have been accepted for the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2 - 6, 2023 in Chicago, IL. Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: Interim results for the non-small cell lung cancer (NSCLC) cohort. Leveraging innate immunity withAFM24, a novel CD 16A and epidermal growth factors receptor (EGFR) bis pecific innate cell engager: interim results for the non- small cell lung cancer (NSCL CRC) cohort.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.1 USD | +0.14% | +15.64% | +13.60% |
06-12 | Transcript : Affimed N.V., Q1 2024 Earnings Call, Jun 12, 2024 | |
06-12 | Affimed N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.60% | 108M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- AFMD Stock
- News Affimed N.V.
- Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology American Society of Clinical Oncology